Receptor de folato alfa (FRα) alta expresión (≥75% de las células tumorales viables con membrana ≥2+...

Vista determinista de la entidad fuente YAML. La autoridad clínica sigue con los ID de fuente citados y estado de firma del revisor.

ID	`RF-OVARIAN-FRA-HIGH-ACTIONABLE`
Tipo	Señal de alerta
Situación	reviewed 2026-04-27 \| pending_clinical_signoff
Enfermedades	`DIS-OVARIAN`
Fuentes	`SRC-ESMO-OVARIAN-2024` `SRC-MIRASOL-MOORE-2024` `SRC-NCCN-OVARIAN-2025`

Origen de la bandera roja

Definición	Folate receptor alpha (FRα) high expression (≥75% of viable tumor cells with ≥2+ membrane staining by VENTANA FOLR1 RxDx) in platinum-resistant high-grade serous ovarian carcinoma. Mirvetuximab soravtansine (MIRASOL — mPFS 5.6 vs 4.0 mo, OS 16.5 vs 12.7 mo vs investigator-choice chemo) is FDA-approved 2L+ ADC.
Dirección clínica	intensificar
Categoría	high-risk-biology
Algoritmo de cambios	ALGO-OVARIAN-2L

Lógica de activación

{
  "any_of": [
    {
      "finding": "fra_status",
      "value": "high"
    },
    {
      "finding": "folr1_status",
      "value": "high"
    },
    {
      "finding": "fra_expression",
      "value": "high"
    }
  ],
  "type": "biomarker"
}

Notas

Companion diagnostic: VENTANA FOLR1 (FOLR1-2.1) RxDx Assay (Roche). Other FRα assays not validated for mirvetuximab selection. Re-biopsy at platinum-resistant progression preferred (expression can shift from primary). FRα-medium / -low excluded from MIRASOL labeling — receive AURELIA-style chemo + bev. Class toxicity: ocular AEs (~50% — keratopathy, blurred vision; lubricating drop prophylaxis required, ophthalmology baseline + on-treatment exams). ILD ~3% but routinely watched.

Utilizado por

Algoritmos

ALGO-OVARIAN-2L - ALGO-OVARIAN-2L